---
title: "Leqvio (inclisiran) in hypercholesterolemia: Safety questions"
description: "Safety questions on Leqvio (inclisiran) in hypercholesterolemia, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Safety evidence. Questions: What are the most common side effects of Leqvio? How many patients stopped Leqvio because of side effects? What did ORION-8 show about Leqvio's long-term safety? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Leqvio (inclisiran) in hypercholesterolemia: Safety questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Leqvio](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf)

Safety questions that apply to every indication of Leqvio are on [Leqvio (inclisiran), all indications: Safety](https://www.evicenter.com/medical-information/leqvio/safety).

## Side effects

<a id="leqvio-side-effects"></a>

### What are the most common side effects of Leqvio?

> “The data in Table 1 are derived from 3 placebo-controlled trials that included 1,833 adults with 
> hypercholesterolemia treated with LEQVIO, including 1,682 exposed for 18 months (median treatment duration 
> of 77 weeks) [see Clinical Studies (14)]. The mean age of the population was 64 years, 32% of the population 
> were female, 92% were White, 6% were Black or African American, 1% were Asian, and < 1% were other 
> races; 6% identified as Hispanic or Latino ethnicity. At baseline, 12% of patients had a diagnosis of HeFH and 
> 85% had clinical atherosclerotic cardiovascular disease (ASCVD).  
> Adverse reactions reported in at least 3% of LEQVIO-treated patients, and more frequently than in placebo-
> treated patients, are shown in Table 1. 
> Table 1: Adverse Reactions Occurring in Greater Than or Equal to 3% of LEQVIO-treated Adults with 
> Hypercholesterolemia and More Frequently than with Placebo (Trials 1, 2, and 3) 
> Adverse Reactions 
> Placebo (N = 1,822) 
> % 
> LEQVIO (N = 1,833) 
> % 
> Injection site reaction<sup>a</sup> 
> 2 
> 8 
> Arthralgia  
> 4 
> 5 
> Bronchitis  
> 3 
> 4 
> <sup>a</sup>includes related terms such as: injection site pain, erythema and rash”

Source: [LEQVIO: Prescribing information, page 3, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=3)

Note: Table 1 gives the placebo percentage before the LEQVIO percentage for each adverse reaction.

<a id="leqvio-discontinuation"></a>

### How many patients stopped Leqvio because of side effects?

> “Adverse reactions led to discontinuation of treatment in 2.5% of patients treated with LEQVIO and 1.9% of 
> patients treated with placebo. The most common adverse reactions leading to treatment discontinuation in 
> patients treated with LEQVIO were injection site reactions (0.2% versus 0% for LEQVIO and placebo, 
> respectively).”

Source: [LEQVIO: Prescribing information, page 3, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=3)

## Safety evidence

<a id="leqvio-long-term-side-effects"></a>

### What did ORION-8 show about Leqvio's long-term safety?

> “In ORION-8, an open-label extension study in adults with hypercholesterolemia and ASCVD or at increased risk of CVD<sup>‖</sup> (N=3274), demonstrated:
>
> Long-term safety data were consistent with adult phase 3 clinical trials<sup>1,4</sup>
> No new safety signals<sup>4</sup>”

Source: [LEQVIO: Safety Profile | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/safety#:~:text=In%20ORION%2D8%2C%20an%20open%2Dlabel%20extension,No%20new%20safety)

> “Limitations: Study was not blinded nor controlled and includes inherent self-selection bias for continuing onto the extension trial. The open-label design and absence of a control group may present difficulties in the interpretation of results, allowing comparisons only to baseline values.”

Source: [LEQVIO: Safety Profile | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/safety#:~:text=Limitations%3A%20Study%20was%20not%20blinded,comparisons%20only%20to%20baseline%20values.)

> “<sup>§</sup>209 (6.4%) patients had exposure to LEQVIO for 6+ years, 213 (6.5%) patients had exposure to LEQVIO for 5+ years, 1553 (47.4%) patients had exposure for 4+ years, and 2095 (64%) patients had exposure for 3+ years.<sup>4,5</sup>”

Source: [LEQVIO: Safety Profile | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/safety#:~:text=%286.4%25%29%20patients%20had%20exposure%20to,patients%20had%20exposure%20for%203%2B)

Note: ORION-8 included patients from ORION-9, which the Prescribing Information describes as a trial in adults with HeFH.

## Related pages
- [Medical information: Leqvio (inclisiran): Hypercholesterolemia](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia)
- [Indication](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/guidelines)
